être Venture Capital

être Venture Capital is a venture capital firm based in Santa Cruz, California, founded in 2022. The firm is led by women and focuses on supporting mission-driven entrepreneurs. It specializes in pre-seed and series investments in startup companies, providing both financial backing and advisory services to help these businesses grow and succeed. By emphasizing a commitment to purpose-driven ventures, être Venture Capital aims to foster innovation and sustainability in the entrepreneurial landscape.

Jennifer Kuan

Managing Partner

Hillary Talbot

Managing Partner

3 past transactions

Hexas Biomass

Venture Round in 2022
Hexas Biomass specializes in producing sustainable non-wood biomass derived from a high-yielding perennial crop that can grow in diverse climates with minimal inputs. This nature-based substitute is designed to supplement and replace traditional wood, food crops used for fuel, and fossil fuel-based feedstocks across various industries. The company's primary goal is to facilitate the production of eco-friendly alternatives ranging from fiberboard to sustainable packaging to biofuels, thereby enabling clients to reduce their reliance on wood and petroleum-based materials.

Portico Wellness

Venture Round in 2022
Portico Wellness is a mental health platform designed to facilitate access to mental health services for employees and employers. The platform enables individuals to find, connect with, and schedule appointments with independent psychologists, social workers, and therapists, thereby removing common barriers to mental health care. Additionally, Portico Wellness integrates with employee compensation benefits, streamlining the process for patients seeking mental health support. By focusing on enhancing the accessibility and efficiency of mental health services, Portico Wellness aims to improve overall employee well-being and support organizational health initiatives.

Obatala Sciences

Series A in 2022
Obatala Sciences is a biotechnology company focused on developing an innovative in vitro humanized adipose tissue model system aimed at addressing the significant economic burden of obesity and diabetes. By treating body fat as a functional organ, the company seeks to enhance the understanding of its role in health and disease. Their three-dimensional screening tool simplifies tissue engineering, facilitating disease modeling, cell assays, cell identification, tissue analysis, and drug discovery. This model enables academic and pharmaceutical researchers to efficiently identify effective drug compounds, ultimately reducing the time, cost, and effort associated with testing potential treatments for obesity, diabetes, other metabolic diseases, and related cancers.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.